The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

@article{Arber2016The2R,
  title={The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.},
  author={Daniel A. Arber and Attilio Orazi and Robert P. Hasserjian and Jürgen Thiele and Michael J. Borowitz and Michelle M Le Beau and Clara Derber Bloomfield and Mario Cazzola and James W. Vardiman},
  journal={Blood},
  year={2016},
  volume={127 20},
  pages={
          2391-405
        }
}
The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues was last updated in 2008. [...] Key Method The revisions to the categories of myeloid neoplasms and acute leukemia will be published in a monograph in 2016 and reflect a consensus of opinion of hematopathologists, hematologists, oncologists, and geneticists. The 2016 edition represents a revision of the prior classification rather than an entirely new classification and attempts to incorporate new clinical…Expand
View on PubMed
ashpublications.org
5,004 Citations
Highly Influential Citations
261
Background Citations
968
Methods Citations
419
Results Citations
26

5,004 Citations

Citation Type

Citation Type

Controversies in the recent (2016) World Health Organization classification of acute myeloid leukemia.
  • R. Hasserjian
  • Medicine
  • Best practice & research. Clinical haematology
  • 2021
TLDR
The purpose of this review is to explore areas of potential refinement in the current WHO Classification of AML, both in terms of its criteria defining the disease as well as the specific disease subtypes. Expand
Changes in the World Health Organization 2016 classification of myeloid neoplasms everyone should know
TLDR
The growing body of genetic data have not only altered the classification of myeloid neoplasms, but are also impacting patient management, and the disease categories in the new classification facilitate the application of risk- adapted therapy based on the most recently available data. Expand
Genetic Testing in the Diagnosis and Biology of Myeloid Neoplasms (Excluding Acute Leukemias).
TLDR
The workshop underscoring the need for careful management of genetic data by the pathologist and clinician, in the context of other findings highlighted the significance of genetic aberrations in the diagnosis and treatment of non-acute leukemia myeloid neoplasms. Expand
The 2016 WHO classification of acute myeloid leukemia: What the practicing clinician needs to know.
  • D. Arber
  • Medicine
  • Seminars in hematology
  • 2019
TLDR
This review summarizes the WHO approach as well as the priority of specific features for disease classification of acute myeloid leukemia, including AML with myelodysplasia-related changes, and changes to specific categories. Expand
The 2016 revision to the World Health Organization classification of myelodysplastic syndromes
  • M. Hong, G. He
  • Medicine
  • Journal of translational internal medicine
  • 2017
TLDR
The new revised classification of MDS introduced refinements in the cytopenia and morphological changes, and also the influence of genetic information in MDS diagnosis and classification. Expand
Diagnosis of Myeloproliferative Neoplasms: Current Perspectives from Recent Research
TLDR
This newer 2017 classification of tumors of the hematopoietic and lymphoid tissues retains the basic approach hinged on clinical characteristics, morphological features, immunophenotype, and cytogenetics (CTG). Expand
Practical Implications of the 2016 Revision of the World Health Organization Classification of Lymphoid and Myeloid Neoplasms and Acute Leukemia.
TLDR
This review highlights the key aspects of the 2016 update of the WHO classification of lymphoid and myeloid neoplasms and acute leukemia with particular importance to routine patient care and clinical trial design. Expand
Conventional cytogenetics for myeloid neoplasms in the era of next‐generation‐sequencing
TLDR
How multiple diagnostic techniques should be integrated in the diagnosis of acute myeloid leukemia (AML) and the risk stratification of patients is discussed and karyotype is included as a fundamental component of prognostic assessment. Expand
Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories.
TLDR
The data support the inclusion of MP- CMML and MDS-CMML subtypes in the WHO 2017 revision and support the 3-tiered blast-based system is not well supported in this study. Expand
An update on classification, genetics, and clinical approach to mixed phenotype acute leukemia (MPAL)
TLDR
There is a lack of prospective trial data to guide therapy; treatment generally relies on ALL-like regimens followed by consolidation chemotherapy or hematopoietic stem cell transplant (HSCT). Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 168 REFERENCES
Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system.
TLDR
Clinical, morphologic, and cytogenetic criteria for this 2008 WHO AML category, AML with myelodysplasia-related changes, support the clinical, pathologic, cytogenetics, and molecular features of 100 patients evaluated. Expand
Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients.
TLDR
In the 2008 WHO classification scheme, FAB subclassification does not provide prognostic information for "AML, NOS" cases if data on NPM1 and CEBPA mutations are available. Expand
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.
TLDR
The classification of myeloid neoplasms and acute leukemia is highlighted with the aim of familiarizing hematologists, clinical scientists, and hematopathologists not only with the major changes in the classification but also with the rationale for those changes. Expand
Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management
TLDR
Although second and third generation TKIs are potent and specific BCR‐ABL TK is, they exhibit unique pharmacological profiles and response patterns relative to different patient characteristics, such as patients comorbidities, disease stage, and BCR-ABL mutational status. Expand
Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification.
TLDR
A retrospective, multi-institutional study of patients with AEL suggests that AEL is in the continuum of MDS and AML with erythroid hyperplasia, where karyotype rather than an arbitrary blast cutoff represents the most important prognostic factor. Expand
Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms
TLDR
The results support the use of the histological criteria proposed by the WHO classification for the Philadelphia chromosome-negative myeloproliferative neoplasms to ensure a more precise and early diagnosis for these patients. Expand
The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features
TLDR
The current ‘spotlight’ review provides practical guidelines, which should allow for a reproducible classification of these uncommon neoplasms when encountered in clinical practice, and is being replaced by ‘MDS/MPN’ that will be used in this review. Expand
Should myeloid and lymphoid neoplasms with PCM1‐JAK2 and other rearrangements of JAK2 be recognized as specific entities?
TLDR
It is suggested that lymphoid and myeloid neoplasms associated with t(8;9)(p22;p24); PCM1‐JAK2 fusion should be recognized as an entity. Expand
Revised international prognostic scoring system for myelodysplastic syndromes.
TLDR
This revised IPSS-R comprehensively integrated the numerous known clinical features into a method analyzing MDS patient prognosis more precisely than the initial IPSS and should prove beneficial for predicting the clinical outcomes of untreated MDS patients and aiding design and analysis of clinical trials in this disease. Expand
Pediatric myelodysplasia: a study of 68 children and a new prognostic scoring system.
TLDR
A modified FAB type, platelet count, Hb F level, and cytogenetic complexity scoring system may prove helpful in making treatment choices in pediatric MDS and now needs to be tested prospectively in large scale population-based studies. Expand
...
1
2
3
4
5
...